Despite the recent general advances in prostate imaging and genetic testing, the actual diagnosis of PCa is still based on the dosing of total serum prostate specific antigen (PSA), the digital rectal examination (DRE) as screening methods and on the ultrasound-guided 12-core systematic prostate biopsy as confirmation method [2]. This evidence concerns the gene KLK3 and posterior cortical atrophy.